hydration room semaglutide IV Therapy Wellness Services: IV Therapy, Shots,

Phase 1 data published 2021, Phase 2 data published 2023 (NEJM), the Phase 3 program TRIUMPH is ongoing: TRIUMPH-1 , Phase 3 obesity without T2D (n=2,100), results Q4 2025 TRIUMPH-2 , Phase 3 obesity + T2D (n=1,800), results 2026 TRIUMPH-3 , Phase 3 obesity + CV disease (n=1,900), results 2026 TRIUMPH-4 , Phase 3 obesity + knee osteoarthritis, results 2026 TRIUMPH-OUTCOMES , Phase 3 cardiovascular outcome trial (n=15,000+), results 2027 to 2028 FDA approval is expected at the earliest 2026 to 2027 in the obesity indication, similarly for T2DM

Currently, only Wegovy and Saxenda are However, researchers show there is a growing number of people without diabetes The amount of weight a person may lose on a GLP-1 agonist varies

Sulforaphane inhibited rotenone-induced neuronal apoptosis by restoring the mTOR pathway Disturbances in the balance of mTOR activity in the brain can impair neuronal functions and have detrimental consequences on neuronal regeneration after damage 40

A novel biologically active seleno-organic compound-1: Gultathione peroxidase-like activity in vitro and antioxidant capacity of PZ-51(Ebselen)

Yau M, Sperling M

Autism and intellectual disability associated with mitochondrial disease and hyperlactacidemia